Technical Analysis for TGTX - TG Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Stochastic Reached Overbought | Strength | -1.34% | |
| Wide Bands | Range Expansion | -1.34% | |
| Overbought Stochastic | Strength | -1.34% | |
| Wide Bands | Range Expansion | 2.31% | |
| Wide Bands | Range Expansion | 6.62% | |
| Down 3 Days in a Row | Weakness | 6.62% | |
| Calm After Storm | Range Contraction | 4.73% |
| Alert | Time |
|---|---|
| Down 1% | about 14 hours ago |
| Possible NR7 | about 16 hours ago |
| Reversed from Up | about 17 hours ago |
| Gap Up Closed | about 19 hours ago |
| 60 Minute Opening Range Breakdown | about 19 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 04/29/2024
TG Therapeutics, Inc. Description
TG Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company is developing two advanced therapies targeting hematological malignancies. The TGTX-1101 (ublituximab) is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes, which is in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. The TGR-1202 is an orally available PI3K delta inhibitor believed to be important in the proliferation and survival of B-lymphocytes. TG Therapeutics, Inc. is headquartered in New York, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Development Treatment Of Cancer Pharmaceutical Products Monoclonal Antibodies Monoclonal Antibody Lymphoma Hematological Malignancies Lymphocytes Antibody Drug Conjugate Camidanlumab Tesirine Cd20
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 31.5178 |
| 52 Week Low | 6.465 |
| Average Volume | 3,417,917 |
| 200-Day Moving Average | 13.20 |
| 50-Day Moving Average | 15.37 |
| 20-Day Moving Average | 15.52 |
| 10-Day Moving Average | 17.00 |
| Average True Range | 0.88 |
| RSI (14) | 68.25 |
| ADX | 30.67 |
| +DI | 37.57 |
| -DI | 13.90 |
| Chandelier Exit (Long, 3 ATRs) | 15.78 |
| Chandelier Exit (Short, 3 ATRs) | 15.56 |
| Upper Bollinger Bands | 18.72 |
| Lower Bollinger Band | 12.31 |
| Percent B (%b) | 0.84 |
| BandWidth | 41.31 |
| MACD Line | 0.78 |
| MACD Signal Line | 0.48 |
| MACD Histogram | 0.2973 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 18.89 | ||||
| Resistance 3 (R3) | 18.99 | 18.70 | 18.70 | ||
| Resistance 2 (R2) | 18.70 | 18.40 | 18.65 | 18.63 | |
| Resistance 1 (R1) | 18.21 | 18.22 | 18.07 | 18.11 | 18.56 |
| Pivot Point | 17.92 | 17.92 | 17.85 | 17.87 | 17.92 |
| Support 1 (S1) | 17.43 | 17.62 | 17.29 | 17.33 | 16.88 |
| Support 2 (S2) | 17.14 | 17.44 | 17.09 | 16.81 | |
| Support 3 (S3) | 16.65 | 17.14 | 16.75 | ||
| Support 4 (S4) | 16.55 |
